BamSEC and AlphaSense Join Forces
Learn More

Savara Inc. – Articles of Incorporation

NASDAQ: SVRA    
Share price (3/30/26): $5.05    
Market cap (3/30/26): $1.034 billion
Search in Documents
Key Exhibits
External Links

Articles of Incorporation Filter

EX-3.1
from 10-Q 7 pages Mast Therapeutics, Inc. Amended and Restated Certificate of Incorporation
12/34/56
EX-3.1
from 10-Q 7 pages Mast Therapeutics, Inc. Amended and Restated Certificate of Incorporation
12/34/56
EX-3.1
from 8-K 1 page Savara Inc. Certificate of Amendment of the Amended and Restated Certificate of Incorporation
12/34/56
EX-3.1
from 8-K 21 pages Amended and Restated Bylaws of Savara Inc. (A Delaware Corporation) March 28, 2023
12/34/56
EX-3.1
from S-3 5 pages Mast Therapeutics, Inc. Amended and Restated Certificate of Incorporation
12/34/56
EX-3.1
from 8-K 1 page Savara Inc. Certificate of Amendment of the Amended and Restated Certificate of Incorporation
12/34/56
EX-3.1
from S-3 4 pages Mast Therapeutics, Inc. Amended and Restated Certificate of Incorporation
12/34/56
EX-3.1
from 8-K 1 page Savara Inc. Certificate of Amendment of the Amended and Restated Certificate of Incorporation
12/34/56
EX-3.1
from 8-K 3 pages Mast Therapeutics, Inc. Amended and Restated Certificate of Incorporation
12/34/56
EX-3.2
from 10-K 17 pages Composite Amended and Restated Bylaws, as Amended of Mast Therapeutics, Inc. (A Delaware Corporation) March 19, 2014
12/34/56
EX-3.1
from 8-K 1 page Certificate of Amendment of the Amended and Restated Bylaws of Mast Therapeutics, Inc
12/34/56
EX-3.1
from S-1 3 pages Composite Amended and Restated Certificate of Incorporation, as Amended of Mast Therapeutics, Inc
12/34/56
EX-3.2
from 8-K ~10 pages Amended and Restated Bylaws of Mast Therapeutics, Inc. (A Delaware Corporation) (Formerly Known as Adventrx Pharmaceuticals, Inc.) March 11, 2013
12/34/56
EX-3.1
from 8-K 1 page Certificate of Ownership and Merger Merging Mast Therapeutics, Inc. With and Into Adventrx Pharmaceuticals, Inc. Pursuant to Section 253 of the General Corporation Law of the State of Delaware Sixth: This Certificate of Ownership and Merger Shall Be Effective as of 12:01 A.M. Eastern Time on March 11, 2013. 1 in Witness Whereof, the Corporation Has Caused This Certificate of Ownership and Merger to Be Executed by Its Duly Authorized Officer This 28th Day of February 2013
12/34/56
EX-3.1
from 8-K 1 page Certificate of Amendment of the Amended and Restated Bylaws of Adventrx Pharmaceuticals, Inc
12/34/56
EX-3.2
from 8-K 1 page Certificate of Amendment of the Amended and Restated Bylaws of Adventrx Pharmaceuticals, Inc
12/34/56
EX-3.1
from 8-K 1 page Certificate of Elimination of the 0% Series a Convertible Preferred Stock, 5% Series B Convertible Preferred Stock, 5% Series C Convertible Preferred Stock, 4.25660% Series D Convertible Preferred Stock, 3.73344597664961% Series E Convertible Preferred Stock, and 2.19446320054018% Series F Convertible Preferred Stock of Adventrx Pharmaceuticals, Inc. Pursuant to Section 151(g) of the General Corporation Law of the State of Delaware
12/34/56
EX-3.1
from 8-K 26 pages Adventrx Pharmaceuticals, Inc. Certificate of Designation of Preferences, Rights and Limitations of 2.19446320054018% Series F Convertible Preferred Stock Pursuant to Section 151 of the Delaware General Corporation Law
12/34/56
EX-3.1
from 8-K 1 page Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Adventrx Pharmaceuticals, Inc. Pursuant to Sections 228 and 242 of the General Corporation Law of the State of Delaware
12/34/56
EX-3.1
from 8-K 26 pages Adventrx Pharmaceuticals, Inc. Certificate of Designation of Preferences, Rights and Limitations of 3.73344597664961% Series E Convertible Preferred Stock Pursuant to Section 151 of the Delaware General Corporation Law
12/34/56